Scientific literature consistently lists these potential benefits of skin allograft use on chronic wounds: Minimizes infection and keeps the wound bed mechanically clean; acts as a bacterial barrier; decreases loss of protein, water, and electrolyte; reduces pain; decreases incidence of contractures; may provide a “dose pack” of growth factors to wound bed; prevents desiccation of bone and tendon; stimulates re-epithelialization and wound neovascularization.
SnyderR J. Treatment of nonhealing ulcers with allografts. Clin Dermatol. 2005;23:388–395
SpenceR J, WongL. The enhancement of wound healing with human skin allograft. Surg Clin North Am. 1997;77:3,731-745
AlloSkin™ RT meshed human dermal graft is a sterile skin graft for acute and chronic wound therapy. Skin allografts may mechanically protect the wound and provide biologic factors native to human skin, which may help stimulate the wound healing process.
Our process uses e-beam irradiation to yield a pliable graft with broad clinical applications and room temperature storage, eliminating the need for costly cryo freezers. Extensive serological and microbiological testing increases safety of skin allografts.
As a homologous-use allograft (FDA 21 CFR 1271), AlloSkin may be used to repair any integumental defect, such as those caused by ulcers and burns, and is appropriate for use over exposed substructures, such as bone, tendon, ligament, and muscle. Sterile tissue should be stored at room temperature.
